IP Library Granted Patent US 8,680,334
Granted Patent B2
US 8,680,334 · App. 13/772,572 · Granted Mar 25, 2014

Process for the preparation of iosimenol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,680,334
App. No.
13/772,572
Granted
Mar 25, 2014
Kind
B2
Abstract

A process for the preparation of iosimenol comprising reacting 5,5′-[(1,3-dioxo-1,3-propanediyl)diimino]bis[N-(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide] (C-VI) with a 3-halo-1,2-propanediol in an aqueous solvent. A process for the preparation of C-VI comprising reacting 3,3′-[(1,3-dioxo-1,3-propanediyl)diimino]bis[5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride] (C-V) with 3-amino-1,2-propanediol in the presence of an inorganic base and a suitable non-aqueous polar solvent. A process for the preparation of C-V comprising reacting 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride (C-IV) with malonyl dichloride in a solvent comprising a suitable ester solvent, a suitable nitrile solvent or mixtures thereof.

Claims (16)

1. A process for the preparation of 3,3′-[(1,3-dioxo-1,3-propanediyl)diimino]bis[5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride] (C-V) comprising reacting 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride (C-IV) with malonyl dichloride in a solvent comprising a suitable ester solvent, a suitable nitrile solvent or mixtures thereof, wherein C-V and C-IV have the formulae:

2. The process of claim 1 wherein the solvent further comprises a suitable ethereal solvent.

3. The process of claim 1 wherein the solvent is selected from acetonitrile, ethyl acetate, a mixture of acetonitrile and tetrahydrofuran, a mixture of ethyl acetate and tetrahydrofuran, a mixture of acetonitrile and 1,2-dimethoxyethane, a mixture of ethyl acetate and 1,2-dimethoxyethane, or a mixture of acetonitrile and ethyl acetate.

4. The process of claim 3 wherein the solvent is selected from acetonitrile, ethyl acetate, a mixture of acetonitrile and tetrahydrofuran, a mixture of ethyl acetate and tetrahydrofuran, or a mixture of acetonitrile and ethyl acetate.

5. The process of claim 4 wherein the solvent comprises acetonitrile or a mixture of acetonitrile and tetrahydrofuran.

6. The process of claim 5 wherein the solvent is a mixture of acetonitrile and tetrahydrofuran wherein the weight ratio of acetonitrile:tetrahydrofuran is about 1:9 to about 49:1.

7. The process of claim 6 wherein the weight ratio of acetonitrile:tetrahydrofuran is about 1:1 to about 49:1.

8. The process of claim 4 wherein the solvent is ethyl acetate or a mixture of ethyl acetate and tetrahydrofuran.

9. The process of claim 8 wherein the solvent is a mixture of ethyl acetate and tetrahydrofuran wherein the weight ratio of ethyl acetate:tetrahydrofuran is about 1:9 to about 49:1.

10. The process of claim 9 wherein the weight ratio of ethyl acetate:tetrahydrofuran is about 1:1 to about 49:1.

11. The process of claim 1 wherein compound C-V is formed as a particulate precipitate in the solvent system, and wherein the compound C-V particles have a particle size larger than compound C-V particles prepared in a solvent system comprising only ethereal solvents.

12. The process of claim 7 wherein the weight ratio of acetonitrile:tetrahydrofuran is about 3:1 to about 9:1.

13. The process of claim 10 wherein the weight ratio of ethyl acetate:tetrahydrofuran is about 3:1 to about 9:1.

14. The process of claim 5 further comprising isolating particles of compound C-V by filtration, wherein the rate of filtration is greater than the rate of filtration for compound C-V prepared in a solvent system comprising only ethereal solvents.

15. The process of claim 14 wherein the weight ratio of acetonitrile:tetrahydrofuran is about 9:1 or greater.

16. The process of claim 8 further comprising isolating particles of compound C-V by filtration, wherein the rate of filtration is greater than the rate of filtration for compound C-V prepared in a solvent system comprising only ethereal solvents.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →